Portal de Periódicos da CAPES

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients

2017; Adis, Springer Healthcare; Volume: 17; Issue: 1 Linguagem: Inglês

10.1007/s40268-017-0174-z

1179-6901

José Antonio Mata‐Marín, Ariane Estrella Weiser Smeke, Mariana Rotzinger Rodriguez, Marcelino Chávez-García, Marco Isaac Banda-Lara, Alma Minerva Pérez Ríos, Nohemí Núñez-Rodríguez, Juan Carlos Domínguez-Hermosillo, Alberto Chaparro Sánchez, Irene Juárez-Kasusky, Javier Enrique Cruz Herrera, Jorge Luis Sandoval Ramírez, Jesús Gaytán‐Martínez,

HIV/AIDS Research and Interventions

We evaluated the effectiveness of a raltegravir (RAL)-containing regimen plus an optimized background regimen in HIV-1 highly treatment-experienced patients. A retrospective cohort, multicentre study was conducted. Adult (>16 years old) HIV treatment-experience patients starting therapy with a RAL-containing regimen were included. Effectiveness was evaluated as the percentage of patients with an undetectable HIV-1 RNA viral load (<50 and <200 copies/mL) after 48 weeks, and changes in CD4+ cell counts. We evaluated the risk factors associated with treatment failure. Of the 107 patients in the cohort, 86% were men, the median age was 45 years [interquartile range (IQR) 40–52] and the median number of previous regimens was six (IQR 4–7). After 48 weeks of treatment, 73% (IQR 63–80%) of patients (n = 78) had a viral load of <50 copies/mL and 85% (IQR 77–90%) (n = 91) had <200 copies/mL. In a logistic regression model, risk factors associated with a virological outcome of HIV-1 RNA of 40 years [odds ratio (OR) 5.61; 95% confidence interval (CI) 1.61–18.84; P = 0.006] and use of tenofovir in the regimen (OR 0.16; 95% CI 0.03–0.80; P = 0.026). In this Mexican cohort, RAL achieved high rates of virological suppression and an increase in CD4+ cell count in highly treatment-experienced patients infected with HIV-1. Age >40 years was associated with a good virological outcome, contrary to tenofovir use, which was associated with a poor virological outcome.